1. Introduction
===============

Mutations in proteins that chemically modify chromatin, or possess reader domains to bind these modifications are now documented in a growing number of developmental diseases \[[@B1-genes-06-00325]\]. More recently, the high-throughput screening of various cancer genomes using next-generation screening technologies (e.g., Roche/454, Illumina/Solexa) has yielded mutations in many of these same epigenetic regulators \[[@B2-genes-06-00325],[@B3-genes-06-00325],[@B4-genes-06-00325]\]. These mutations target genes encoding proteins that are responsible for ATP-dependent nucleosome reorganization (e.g., ATRX), histone tail modifiers (e.g., JARID1C), histone variants (e.g., histone H3.3), DNA methyltransferases (e.g., DNMT3A/B), and proteins that interface with chromatin (e.g., MECP2) \[[@B4-genes-06-00325],[@B5-genes-06-00325],[@B6-genes-06-00325],[@B7-genes-06-00325],[@B8-genes-06-00325]\]. Here, we review recent advances in a gene that encodes another such protein, *plant homeodomain finger protein 6* (*PHF6*), which possesses two chromatin-binding zinc finger domains and has been implicated in the Börjeson--Forssman--Lehmann X-linked intellectual disability syndrome (BFLS), T-cell acute lymphoblastic leukemia (T-ALL), and acute myeloid leukemia (AML) \[[@B9-genes-06-00325],[@B10-genes-06-00325],[@B11-genes-06-00325]\].

1.1. Structure and Expression Pattern of PHF6
---------------------------------------------

The *PHF6* (Gene ID: 84295) gene is located on the X chromosome, consists of 11 exons, and is transcribed into a 4.5 kb mRNA (see [Figure 1](#genes-06-00325-f001){ref-type="fig"}A). Exons 2--10 encode a 365 amino acid (41 kDa) protein (Uniprot: Q8IWS0) (see [Figure 1](#genes-06-00325-f001){ref-type="fig"}B), while exons 1 and 11 comprise the 5' and 3' untranslated regions (UTRs), respectively. Two mRNA isoforms exist in humans, with the second incorporating intron 10 to increase the size of the 3' UTR \[[@B9-genes-06-00325]\]. A third isoform is predicted to encode a truncated 312 amino acid version of the PHF6 protein, but its existence has not been confirmed experimentally \[[@B12-genes-06-00325]\]. The PHF6 protein is highly conserved among vertebrates, with 97.5% amino acid identity between humans and mice. Invertebrates do not have a *PHF6* homolog. Structurally, the most prominent features of PHF6 are its two nearly identical zinc finger domains (ZaP1: aa 14--134; ZaP2: aa 209--332) that are derived from a PZP motif \[[@B13-genes-06-00325]\]. PZP motifs consist of a [P]{.ul}HD domain, followed by a [z]{.ul}inc knuckle, followed by an atypical [P]{.ul}HD domain, however each zinc finger domain of PHF6 is a degenerate version of this structure as they consist only of the [z]{.ul}inc knuckle and the [a]{.ul}typical [P]{.ul}HD (ZaP) \[[@B14-genes-06-00325]\]. PHF6 also contains two nuclear localization sequences (NLS1: aa 13--16; NLS2: aa 129--133) and a nucleolar localization sequence (NoLS: 157--169), with the localization of PHF6 to the nucleus and nucleolus having been confirmed by immunocytochemistry, subcellular fractionation, and mass spectrometry-based identifications \[[@B9-genes-06-00325],[@B14-genes-06-00325],[@B15-genes-06-00325],[@B16-genes-06-00325],[@B17-genes-06-00325],[@B18-genes-06-00325]\].

To date, no *Phf6* animal knockout models have been published and few studies record its gene expression patterns during embryonic and postnatal mouse development. In mice, *Phf6* expression has been observed to be ubiquitous, with particularly high expression in the brain and central nervous system (CNS) throughout embryonic development, and more moderate expression during post-natal development and in adult tissues \[[@B19-genes-06-00325]\]. Particularly high PHF6 expression is observed in the cortical plate and intermediate zone at E14.5, as well as the ventricular and subventricular zones by E16.5 \[[@B20-genes-06-00325]\]. *Phf6* is also highly expressed in other embryonic tissues, including the anterior pituitary at E12.5, nasal processes from E9.5 to E12.5, pharyngeal arches at E9.5, and limb buds at E12.5. In another study, *Phf6* expression was elevated in murine T-cell lymphoma, supporting observations of high *PHF6* expression in human adult B- and T-lymphoid cells \[[@B11-genes-06-00325],[@B15-genes-06-00325]\]. Thus, collectively, these expression studies are indicative of a potential role for PHF6 during both neurogenesis and hematopoiesis.

![*PHF6* gene and protein domain structures. (**A**) The *PHF6* gene contains 11 exons and is located on the X chromosome. Source: UCSC Genome Browser \[[@B21-genes-06-00325]\]. (**B**) The gene encodes a protein of 365 amino acids with two ZaP ([z]{.ul}inc knuckle, [a]{.ul}typical [P]{.ul}HD) domains and localization signals for the nucleus (**~\*~**) and nucleolus (••).](genes-06-00325-g001){#genes-06-00325-f001}

1.2. Regulation of PHF6 Transcripts
-----------------------------------

The epigenetic mechanisms that regulate *PHF6* transcription have not been well characterized aside from the identification of a NOTCH1 binding site and DNA methylation sites in the *PHF6* promoter \[[@B22-genes-06-00325],[@B23-genes-06-00325]\]. Post-transcriptionally, *PHF6* mRNA is targeted by as many as 25 microRNAs, including miR-20a, miR-26a, miR-128, and miR-574 \[[@B20-genes-06-00325],[@B24-genes-06-00325],[@B25-genes-06-00325]\]. Franzoni *et al.* recently described that miR-128, which has three binding sites in the *Phf6* 3' UTR, is essential for mediating the switch between neuronal migration and neurite outgrowth by silencing *Phf6* in upper level cortical neurons \[[@B20-genes-06-00325]\]. Indeed the downregulation of *Phf6* that occurs in these cortical layers during development was inversely correlated with an increase in the expression levels of miR-128. Interestingly, miR-128 is also oncogenically expressed in tumours arising from non-neuronal tissue, including T-ALL, where *PHF6* was confirmed as a target \[[@B25-genes-06-00325]\].

2. Consequences of Germline Mutations of *PHF6*
===============================================

2.1. Börjeson--Forssman--Lehmann Syndrome (BFLS)
------------------------------------------------

The BFLS phenotype was first reported a half century ago and the multiple variable aspects of the phenotype have been well described in the literature \[[@B26-genes-06-00325],[@B27-genes-06-00325],[@B28-genes-06-00325],[@B29-genes-06-00325],[@B30-genes-06-00325]\]. The majority of BFLS cases occur in males who display developmental delay within their first year after birth, with mild to severe intellectual disability becoming apparent during childhood and adolescence \[[@B27-genes-06-00325],[@B28-genes-06-00325]\]. Additional features of the BFLS phenotype include large ears, coarse facial features (e.g., deep set eyes), long tapered fingers, syndactyly and shortening of the toes, gynecomastia, truncal obesity, hypogonadism, hypotonia, and feeding problems during infancy. Some features are present at birth (e.g., hypogonadism), however other aspects of the phenotype present themselves during childhood and adolescence (e.g., coarse facial features, truncal obesity). Gynecomastia in particular emerges during adolescence, although it is unclear if it is caused by breast tissue hyperplasia or lipomastia \[[@B29-genes-06-00325]\]. Less common features of BFLS include microcephaly/macrocephaly, short stature, epilepsy, cleft lip and palate, hearing impairment, and hypopituitarism \[[@B28-genes-06-00325]\]. Two independent probands have also been diagnosed with bone marrow cancers, including Hodgkin's lymphoma and T-ALL \[[@B29-genes-06-00325],[@B31-genes-06-00325]\]. Female carriers within BFLS families typically display mild, if any, symptoms, with at least one isolated female patient expressing a *de novo PHF6* mutation having been diagnosed with BFLS marked by mild intellectual disability \[[@B32-genes-06-00325]\].

While BFLS was long known to be X-linked, having been previously mapped to the Xq26--27 chromosomal region, it was not until 2002 that *PHF6* mutations were identified as its cause \[[@B9-genes-06-00325],[@B33-genes-06-00325],[@B34-genes-06-00325],[@B35-genes-06-00325]\]. These mutations include missense mutations, nonsense mutations, and deletions (see [Table 1](#genes-06-00325-t001){ref-type="table"}). These mutations are distributed across the entire *PHF6* gene, suggesting that the associated BFLS phenotypes arise from a loss of PHF6 function, however attempts to identify genotype-phenotype correlations between specific *PHF6* mutations and the severity of intellectual disability have not been successful \[[@B29-genes-06-00325],[@B30-genes-06-00325]\]. To date, no other gene mutations are known to cause BFLS, however not all BFLS patients have an identified *PHF6* mutation. In one cohort, for instance, *PHF6* mutations were only identified in 5/25 patients, indicating that there could be additional BFLS loci, or more likely, that the clinical diagnosis of BFLS overlaps with other syndromes \[[@B32-genes-06-00325]\]. In this regard, many X-linked intellectual disability syndromes (e.g., Coffin--Lowry syndrome, Klinefelter syndrome, Prader--Willi syndrome, Wilson--Turner syndrome) share overlapping phenotypes with BFLS such as gynecomastia, obesity, hypotonia, hypogonadism, or digit abnormalities \[[@B28-genes-06-00325],[@B36-genes-06-00325]\].

2.2. Coffin--Siris syndrome
---------------------------

First described in 1970, Coffin--Siris syndrome (reviewed by \[[@B37-genes-06-00325],[@B38-genes-06-00325]\]) is an intellectual disability disorder that is caused by mutations in genes encoding individual subunits of the BAF (BRG1/BRM-associated factor) complex, including *ARID1A*, *ARID1B*, *SMARCA2*, *SMARCA4* (*BRG1*), *SMARCB1* (*INI1*), and *SMARCE1* (*BAF57*) \[[@B39-genes-06-00325],[@B40-genes-06-00325]\]. Interestingly, several recent studies describe female patients expressing *de novo PHF6* mutations that exhibit more severe intellectual disability than female BFLS carriers, overlapping more closely with Coffin--Siris syndrome than with features of classical BFLS \[[@B30-genes-06-00325],[@B41-genes-06-00325],[@B42-genes-06-00325],[@B43-genes-06-00325],[@B44-genes-06-00325]\]. Distinguishing features of this newly described phenotype include sparse hair, deep set eyes, hypoplasia of the fifth digit, linear skin hyperpigmentation, and dental abnormalities \[[@B44-genes-06-00325]\]. Unlike male BFLS patients, these females do not display truncal obesity and syndactyly occurs between the third and fifth toes, rather than between the second and third toes \[[@B42-genes-06-00325],[@B44-genes-06-00325]\]. Notably, *de novo PHF6* mutations in females primarily consist of deletions or frameshift mutations (see [Table 1](#genes-06-00325-t001){ref-type="table"}) in comparison to male BFLS patients or female carriers, which more commonly express point mutations. Furthermore, it is tantalizing to speculate that these more deleterious mutations might be lethal in males.

Female patients with *de novo PHF6* mutations are nearly indistinguishable from Coffin--Siris syndrome patients during early infancy, but develop a more distinct phenotype as they age, such as the display of linear skin hyperpigmentation, which does not occur in Coffin--Siris syndrome patients \[[@B30-genes-06-00325],[@B41-genes-06-00325]\]. Interestingly, females that lack linear skin hyperpigmentation exhibit a phenotype that more closely resembles classical BFLS than the Coffin--Siris-like phenotype. Indeed, Zweier *et al.* argue that functional mosaicism from variable rates of skewed X-chromosome inactivation in different tissues drives the Coffin--Siris-like phenotype \[[@B30-genes-06-00325]\]. In this regard, every documented case of a female patient expressing a *de novo PHF6* mutation has presented with skewed X-chromosome inactivation (in peripheral blood) of 93% or higher, yet they present with a severe phenotype \[[@B30-genes-06-00325]\]. However, analysis of fibroblast cells in some Coffin--Siris-like patients has demonstrated variable X-inactivation (58%--83%) suggesting that reduced X-inactivation skewing in other tissues is what contributes to the phenotypic differences \[[@B42-genes-06-00325]\]. Consistent with this idea, there is no correlation with the level of skewing in peripheral blood cells in BFLS carriers with or without a phenotype \[[@B29-genes-06-00325],[@B42-genes-06-00325],[@B43-genes-06-00325]\]. Therefore, whether or not female patients expressing a *PHF6* mutation develop BFLS or the Coffin--Siris-like phenotype may depend upon the type of mutation (deletion *vs.* point mutation) and on the extent to which skewed X-chromosome inactivation occurs in different tissues.
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###### 

Summary of germline *PHF6* mutations.

  Gender   Nucleotide Change     Amino Acid Change   Type of Mutation   Location of Mutation   Cancer   Isolated^3^/ *De novo*   Reference
  -------- --------------------- ------------------- ------------------ ---------------------- -------- ------------------------ -------------------------------------------------
  M        c.2T\>C               p.M1T               Missense           Exon 2                                                   \[[@B9-genes-06-00325]\]
  M        c.2T\>C               p.M1T               Missense           Exon 2                                                   \[[@B32-genes-06-00325]\]
  M        c.134G\>A             p.C45Y              Missense           Exon 2                                                   \[[@B9-genes-06-00325]\]
  M        c.134G\>A             p.C45Y              Missense           Exon 2                          Isolated                 \[[@B9-genes-06-00325]\]
  M        c.266G\>T             p.G89V              Missense           Exon 4                                                   \[[@B45-genes-06-00325]\]
  M        c.296G\>T             p.C99F              Missense           Exon 4                          Isolated                 \[[@B9-genes-06-00325]\]
  M, F     c.686A\>G             p.H229R             Missense           Exon 7                                                   \[[@B9-genes-06-00325]\]
  M        c.700A\>G             p.K234E             Missense           Exon 7                                                   \[[@B9-genes-06-00325]\]
  M        c.769A\>G             p.R257G             Missense           Exon 8                                                   \[[@B9-genes-06-00325]\]
  M        c.769A\>G             p.R257G             Missense           Exon 8                 Yes^2^   Isolated                 \[[@B16-genes-06-00325]\]
  M        c.940A\>G             p.I314V             Missense           Exon 9                                                   \[[@B32-genes-06-00325]\]
  M        c.22A\>T              p.K8\*              Nonsense           Exon 2                                                   \[[@B9-genes-06-00325]\]
  F        c.955C\>T             p.R319\*            Nonsense           Exon 9                          De novo                  \[[@B42-genes-06-00325]\]
  M        c.1024C\>T            p.R342\*            Nonsense           Exon 10                         De novo                  \[[@B26-genes-06-00325],[@B28-genes-06-00325]\]
  M        c.1024C\>T            p.R342\*            Nonsense           Exon 10                                                  \[[@B9-genes-06-00325]\]
  M        c.1024C\>T            p.R342\*            Nonsense           Exon 10                                                  \[[@B9-genes-06-00325]\]
  M        c.1024C\>T            p.R342\*            Nonsense           Exon 10                                                  \[[@B9-genes-06-00325]\]
  M        c.1024C\>T            p.R342\*            Nonsense           Exon 10                Yes^3^                            \[[@B31-genes-06-00325]\]
  F        c.27dupA              p.G10fs\*21         Frameshift         Exon 2                          De novo                  \[[@B32-genes-06-00325]\]
  M        IVS2--8A\>G           M46fsΔexon3         Frameshift         Exon 3                                                   \[[@B16-genes-06-00325]\]
  F        c.677delG             p.G226fsE\*53       Frameshift         Exon 7                          De novo                  \[[@B41-genes-06-00325]\]
  F        c.914G\>T             p.C305F             Frameshift         Exon 9                          De novo                  \[[@B41-genes-06-00325]\]
  F                                                  Duplication        Exons 4--5                      De novo                  \[[@B42-genes-06-00325]\]
  F                                                  Duplication        Exons 4--5                      De novo                  \[[@B42-genes-06-00325]\]
  F        6 kb deletion                             Deletion           Exons 4--5                      De novo                  \[[@B42-genes-06-00325]\]
  F        100 kb deletion                           Deletion           Exons 6--10                     De novo                  \[[@B44-genes-06-00325]\]
  F        15 kb deletion                            Deletion           Exons 9--11                     De novo                  \[[@B43-genes-06-00325]\]
  M        c.999--1001 delTGA    p.D333del           Deletion           Exon 10                                                  \[[@B46-genes-06-00325]\]
  M        c.999--1001 delTGA    p.D333del           Deletion           Exon 10                                                  \[[@B26-genes-06-00325],[@B28-genes-06-00325]\]
  F        Entire gene deleted                       Deletion           Whole gene                      De novo                  \[[@B42-genes-06-00325]\]
  F        270 kb deletion                           Deletion           Whole gene                      Isolated                 \[[@B44-genes-06-00325]\]

^1^ Isolated refers to instances where the parents have not been screened for *PHF6* mutations.

^2^ Hodgkin's lymphoma

^3^ T-cell acute lymphoblastic leukemia

3. Consequences of Somatic Mutations of *PHF6*
==============================================

3.1. T-Cell Acute Lymphoblastic Leukemia (T-ALL)
------------------------------------------------

Somatic *PHF6* mutations in human tumours were first described for T-ALL patients \[[@B10-genes-06-00325],[@B31-genes-06-00325]\]. Van Vlierberghe and colleagues reported *PHF6* mutations in 16% of pediatric and 38% of adult subjects. In four additional studies, other groups have identified T-ALL-related *PHF6* mutation frequencies varying from 5% to 40% within each cohort \[[@B47-genes-06-00325],[@B48-genes-06-00325],[@B49-genes-06-00325],[@B50-genes-06-00325]\]. While Van Vlierberghe *et al.* reported a significantly higher incidence of PHF6 mutations among males, gender differences were not observed in these later studies. In contrast to male BFLS patient mutations, which are primarily missense, neoplastic *PHF6* mutations overwhelmingly consist of deletions, frameshifts, nonsense mutations, or missense mutations that target zinc ion stabilizing residues in the second ZaP domain (see [Table 2](#genes-06-00325-t002){ref-type="table"}). Collectively, these findings suggest that PHF6 is a tumour suppressor and that these mutations result in a loss of function, consistent with silencing of the *PHF6* promoter by DNA methylation in some T-ALL tumours \[[@B23-genes-06-00325]\].

T-ALL arises from developmentally arrested immature T-cells that express one or more mutations to bypass key developmental checkpoints (*i.e.* β selection, -/+ selection) during thymocyte maturation \[[@B51-genes-06-00325]\]. Many of the mutations contributing to T-ALL involve oncogenic translocation events at the T-cell receptor (TCR) gene loci and are categorized within two groups: (i) those that initiate oncogenesis and define the molecular-genetic subtype of the tumour, and (ii) mutations that are recurrent \[[@B52-genes-06-00325]\]. Major T-ALL subtypes are defined by aberrant oncogenic activation or chromosomal translocation events in genes coding for bHLH proteins (e.g., TAL1), LMO proteins (e.g., LMO1), homeobox proteins (e.g., TLX1, TLX3), or proto-oncogenes (e.g., c-MYB), while recurrent mutations target cell signalling pathways (e.g., NOTCH1, signal transduction), cell cycle regulatory mechanisms, and tumour suppressors (*i.e*. for inactivation) \[[@B52-genes-06-00325]\]. Interestingly, *PHF6* mutations are associated with tumours expressing the *TLX1* and *TLX3* oncogenes \[[@B10-genes-06-00325]\]. Consistent with this observation, *PHF6* is highly expressed in DP cells, the stage at which *TLX1*-induced tumours most commonly experience developmental arrest \[[@B10-genes-06-00325],[@B53-genes-06-00325]\]. Moreover, *PHF6* has also been demonstrated to be a direct target of *TLX1*-mediated repression \[[@B54-genes-06-00325]\]. *PHF6* mutations are also co-expressed with JAK1 mutations, SET-NUP214 translocations, and activating *NOTCH1* mutations, which occur in over half of all T-ALL patients \[[@B48-genes-06-00325],[@B50-genes-06-00325],[@B55-genes-06-00325]\].

3.2. Acute Myeloid Leukemia (AML)
---------------------------------

*PHF6* mutations have also been identified in AML patients (see [Table 2](#genes-06-00325-t002){ref-type="table"}) \[[@B11-genes-06-00325]\]. AML is a heterogeneous cancer that develops in multiple progenitor cell types of the myeloid lineage. Recent profiling of the AML cancer genome with next-generation sequencing has demonstrated that most AML mutations are recurrent, consisting primarily of chromosomal translocation events at specific loci and targeted mutations among a group of 23 genes, including epigenetic regulators such as DNMT3A, TET2, and RUNX1 \[[@B8-genes-06-00325]\]. Van Vlierberghe *et al.* found *PHF6* mutations in 10/353 patients. Similar to T-ALL, *PHF6* mutations primarily consisted of deletions, frameshifts, nonsense mutations and missense mutations targeting zinc ion-stabilizing residues from the second ZaP domain. Additional AML screens by other groups found *PHF6* mutations in 3% of screened tumours \[[@B8-genes-06-00325]\]. Additionally, *PHF6* mutations correlated with reduced overall survival in adult patients and were observed to be co-expressed with *RUNX1* mutations \[[@B8-genes-06-00325],[@B56-genes-06-00325]\]. As of yet, tumours expressing *PHF6* mutations have not been correlated with any specific myeloid progenitor cell type, however *PHF6* expression levels were observed to be higher in hematopoietic stem cells and megakaryocyte/erythroid progenitors than in common myeloid progenitors or granulocyte/macrophage progenitors \[[@B11-genes-06-00325]\].

3.3. PHF6 Loss-of-Function in Other Neoplasias
----------------------------------------------

Isolated cases of loss-of-function *PHF6* mutations in chronic myeloid leukemia (CML) and hepatocellular carcinoma patient tumours have also been reported \[[@B49-genes-06-00325],[@B57-genes-06-00325]\]. Interestingly, shRNA-mediated knockdown of *Phf6* in a murine B-cell acute lymphoblastic leukemia (B-ALL) model was observed to significantly reduce the rates of tumour proliferation, in contrast to both T-ALL and AML models, where the loss of *Phf6* correlates with enhanced tumour progression \[[@B24-genes-06-00325],[@B58-genes-06-00325]\]. Consistent with the B-ALL model, *PHF6* knockdown in a HeLa cell model led to a reduction in rates of cellular proliferation, accompanied by a cell cycle delay at G2/M \[[@B59-genes-06-00325]\]. Thus, the downstream functions of PHF6 leading to tumour suppression in specific cell or tissue types (e.g., lymphoid and myeloid) are not necessarily limited to proliferative or cell cycle regulatory processes. Rather, PHF6 likely participates in additional development regulatory networks that are context-dependent and tissue-specific, with the tumorigenic outcome being influenced by the presence of additional oncogenic mutations. This pathogenic model is analogous to the example provided by BCL11B in developing thymocytes, in which the loss of BCL11B on its own induces massive apoptosis during β-selection, yet also favours T-ALL progression when lost in combination with other oncogenically favourable events \[[@B54-genes-06-00325],[@B60-genes-06-00325]\].
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###### 

Summary of cancer-related *PHF6* mutations.

  Gender   Nucleotide Change                             Amino Acid Change         Type of Mutation     Location of Mutation   Cancer^1^   Reference
  -------- --------------------------------------------- ------------------------- -------------------- ---------------------- ----------- ---------------------------
  F        c.90_91insCCCG                                p.L31PfsX6                Insertion/Deletion   Exon 2                 T-ALL       \[[@B49-genes-06-00325]\]
  M                                                      p.G10fs                   Frameshift           Exon 2                 T-ALL       \[[@B10-genes-06-00325]\]
  M                                                      p.A41fs                   Frameshift           Exon 2                 T-ALL       \[[@B10-genes-06-00325]\]
  M                                                      p.H44fs                   Frameshift           Exon 2                 T-ALL       \[[@B10-genes-06-00325]\]
  F        c.76-95del20+insTTGG                          p.P26fs                   Frameshift           Exon 2                 T-ALL       \[[@B48-genes-06-00325]\]
  M                                                      p.Y105fs                  Frameshift           Exon 3                 T-ALL       \[[@B10-genes-06-00325]\]
  M        c.267_268insTTAGGACC                          p.A90LfsX10               Insertion/Deletion   Exon 4                 T-ALL       \[[@B49-genes-06-00325]\]
  M                                                      p.G122X                   Nonsense             Exon 4                 T-ALL       \[[@B10-genes-06-00325]\]
  M                                                      p.R116X                   Nonsense             Exon 4                 T-ALL       \[[@B10-genes-06-00325]\]
  M                                                      p.T98fs                   Frameshift           Exon 4                 T-ALL       \[[@B10-genes-06-00325]\]
  F        c.289A\>T                                     p.K97X                    Nonsense             Exon 4                 T-ALL       \[[@B48-genes-06-00325]\]
  M                                                      p.H135fs                  Frameshift           Exon 5                 T-ALL       \[[@B10-genes-06-00325]\]
  F                                                      p.F172fs                  Frameshift           Exon 6                 T-ALL       \[[@B10-genes-06-00325]\]
  M                                                      p.R225X                   Nonsense             Exon 6                 T-ALL       \[[@B10-genes-06-00325]\]
  M                                                      p.S158fs                  Frameshift           Exon 6                 T-ALL       \[[@B10-genes-06-00325]\]
  M                                                      p.S191fs                  Frameshift           Exon 6                 T-ALL       \[[@B10-genes-06-00325]\]
  M        c.525_526delGT                                p.S176fs                  Frameshift           Exon 6                 T-ALL       \[[@B48-genes-06-00325]\]
  M        c.673C \> T                                   p.R225X                   Nonsense             Exon 7                 T-ALL       \[[@B49-genes-06-00325]\]
  M        c.653_667delGGGAGGAAGAAAATGinsCCCTTTAAAGGGA   p.G218AfsX                Insertion/Deletion   Exon 7                 T-ALL       \[[@B49-genes-06-00325]\]
  M                                                      p.K235X                   Nonsense             Exon 7                 T-ALL       \[[@B10-genes-06-00325]\]
  M                                                      p.C215Y                   Missense             Exon 7                 T-ALL       \[[@B10-genes-06-00325]\]
  M                                                      p.G263fs                  Frameshift           Exon 8                 T-ALL       \[[@B10-genes-06-00325]\]
  M        c.735M736dupTT                                p.S246FfsX34              Duplication          Exon 8                 T-ALL       \[[@B49-genes-06-00325]\]
  M                                                      p.K273X                   Nonsense             Exon 8                 T-ALL       \[[@B10-genes-06-00325]\]
  M                                                      p.C280Y                   Missense             Exon 8                 T-ALL       \[[@B10-genes-06-00325]\]
  M                                                      p.R257X                   Nonsense             Exon 8                 T-ALL       \[[@B10-genes-06-00325]\]
  M        c.820T\>C                                     p.R274X                   Nonsense             Exon 8                 T-ALL       \[[@B10-genes-06-00325]\]
  M        c.808C\>T                                     p.Q270X                   Nonsense             Exon 8                 T-ALL       \[[@B48-genes-06-00325]\]
  M        c.823G\>A                                     p.G275R                   Missense             Exon 8                 T-ALL       \[[@B48-genes-06-00325]\]
  M        c.779insCGGGAGGATCC                           p.D262fs                  Frameshift           Exon 8                 T-ALL       \[[@B48-genes-06-00325]\]
  M                                                      p.S320X                   Nonsense             Exon 9                 T-ALL       \[[@B10-genes-06-00325]\]
  M        c.903C\>A                                     p.Y301X                   Nonsense             Exon 9                 T-ALL       \[[@B49-genes-06-00325]\]
  M                                                      p.Y303fs                  Frameshift           Exon 9                 T-ALL       \[[@B10-genes-06-00325]\]
  M                                                      p.C283R                   Missense             Exon 9                 T-ALL       \[[@B10-genes-06-00325]\]
  M                                                      p.T300A                   Missense             Exon 9                 T-ALL       \[[@B10-genes-06-00325]\]
  M                                                      p.A311P                   Missense             Exon 9                 T-ALL       \[[@B10-genes-06-00325]\]
  M                                                      p.Y303X                   Nonsense             Exon 9                 T-ALL       \[[@B10-genes-06-00325]\]
  M        c.933_934insT                                 p.A311X                   Nonsense             Exon 9                 T-ALL       \[[@B48-genes-06-00325]\]
  M        c.835delA                                     p.K279fs                  Frameshift           Exon 9                 T-ALL       \[[@B48-genes-06-00325]\]
  M        c.1024C\>T                                    p.R342\*                  Nonsense             Exon 10                T-ALL       \[[@B31-genes-06-00325]\]
  M                                                      p.D333fs                  Frameshift           Exon 10                T-ALL       \[[@B10-genes-06-00325]\]
  M        c.986A\>G                                     p.H329R                   Missense             Exon 10                T-ALL       \[[@B10-genes-06-00325]\]
  M        c.973T\>C                                     p.Y325H                   Missense             Exon 10                T-ALL       \[[@B48-genes-06-00325]\]
  M                                                      p.C215Y                   Missense             Exon 7                 T-ALL       \[[@B10-genes-06-00325]\]
  M                                                      p.C28fs                   Frameshift           Exon 2                 T-ALL       \[[@B10-genes-06-00325]\]
  F        c.968 + 1G \> A                               Undetermined              Non-coding           Intron 9               T-ALL       \[[@B49-genes-06-00325]\]
  M        c.968+2T_968+5GdelTAAG                        Undetermined              Non-coding           Intron 9               T-ALL       \[[@B49-genes-06-00325]\]
  M        0.55 Mb deleted                               Absent                    Deletion             n/a                    T-ALL       \[[@B10-genes-06-00325]\]
  M        0.23 Mb deleted                               Absent                    Deletion             n/a                    T-ALL       \[[@B10-genes-06-00325]\]
  M        1.50 Mb deleted                               Absent                    Deletion             n/a                    T-ALL       \[[@B10-genes-06-00325]\]
  M        0.27 Mb deleted                               Absent                    Deletion             n/a                    T-ALL       \[[@B10-genes-06-00325]\]
  M        1.90 Mb deleted                               Absent                    Deletion             n/a                    T-ALL       \[[@B10-genes-06-00325]\]
  M        0.20 Mb deleted                               Absent                    Deletion             n/a                    T-ALL       \[[@B10-genes-06-00325]\]
  M        0.08 Mb deleted                               Absent                    Deletion             n/a                    T-ALL       \[[@B10-genes-06-00325]\]
  M        0.11 Mb deleted                               Absent                    Deletion             n/a                    T-ALL       \[[@B10-genes-06-00325]\]
  M                                                      p.C20fs                   Frameshift           Exon 2                 AML         \[[@B11-genes-06-00325]\]
  M                                                      p.A40G                    Missense             Exon 2                 AML         \[[@B11-genes-06-00325]\]
  F                                                      p.N171fs                  Frameshift           Exon 6                 AML         \[[@B11-genes-06-00325]\]
  M                                                      p.P200fs                  Frameshift           Exon 7                 AML         \[[@B11-genes-06-00325]\]
  M                                                      p.R274X                   Nonsense             Exon 8                 AML         \[[@B11-genes-06-00325]\]
  M                                                      p.R335fs                  Frameshift           Exon 9                 AML         \[[@B11-genes-06-00325]\]
  M                                                      p.H302Y                   Missense             Exon 9                 AML         \[[@B11-genes-06-00325]\]
  M                                                      p.R319X                   Nonsense             Exon 9                 AML         \[[@B11-genes-06-00325]\]
  M                                                      p.H329L                   Missense             Exon 10                AML         \[[@B11-genes-06-00325]\]
  M                                                      p.R342X                   Nonsense             Exon 10                AML         \[[@B11-genes-06-00325]\]
  M        c.27dupA                                      p.K9RfsX12                Duplication          Exon 2                 AML         \[[@B49-genes-06-00325]\]
  M        c.83_101delGTGGACAGTTACTAATATCinsAT           P.C28YfsX2                Insertion/Deletion   Exon 2                 AML         \[[@B49-genes-06-00325]\]
  M        c.769A\>G                                     p.R257G                   Missense             Exon 8                 HA          \[[@B16-genes-06-00325]\]
  M        c.673C \> T                                   p.R225X                   Nonsense             Exon 7                 HC          \[[@B9-genes-06-00325]\]
  M        c.665C\>T                                     p.A135V                   Missense             Exon 5                 CML         \[[@B57-genes-06-00325]\]
  M        c.670--679del10                               p.N137_E139del140fsX142   Frameshift           Exon 5                 CML         \[[@B57-genes-06-00325]\]
  M        c.895--896delTG                               p.C212WfsX222             Frameshift           Exon 7                 CML         \[[@B57-genes-06-00325]\]

^1^ HA = Hodgkin's lymphoma; HC = Hepatocellular carcinoma; CML = Chronic myeloid leukemia

4. Delineating the Functional Interactions of PHF6
==================================================

Until relatively recently, the role of PHF6 was categorized based on its homology with chromatin remodelling proteins, however several recent studies have shed an early light upon how its molecular responsibilities may contribute to the developmental processes of neurogenesis and hematopoiesis; activities that become compromised during development and/or in cancer. These studies included structural characterization of the PHF6 zinc finger domain, nuclear and nucleolar localization studies, the identification of PHF6-containing protein complexes, and reports of putative phosphorylation sites.

4.1. Functional Analysis of the Conserved Motifs within PHF6
------------------------------------------------------------

In humans, PZP/ZaP domains are primarily found in proteins that participate in transcriptional regulation or changes to chromatin structure (e.g., histone acetylation, methylation, demethylation) (see [Table 3](#genes-06-00325-t003){ref-type="table"}) \[[@B14-genes-06-00325]\]. Canonical PHD domains are Cys4-His-Cys3 type zinc fingers that chelate two zinc ions and participate in protein--protein interactions with post-translationally modified and unmodified histone H3 or H4 histone tails \[[@B61-genes-06-00325],[@B62-genes-06-00325],[@B63-genes-06-00325],[@B64-genes-06-00325],[@B65-genes-06-00325],[@B66-genes-06-00325],[@B67-genes-06-00325]\]. Conversely, the atypical PHD of the ZaP domain is a Cys4-His-Cys2-His type zinc finger, which does not bind histones \[[@B68-genes-06-00325],[@B69-genes-06-00325]\]. Moreover, a ZaP domain carries a net positive charge that is greater than a PHD domain, suggestive of an interaction with a negatively charged substrate \[[@B68-genes-06-00325]\]. Indeed, NMR solution and crystal structures that have recently been derived for the BRPF2 and the PHF6 ZaP2 domains indicate that this structure is able to bind double-stranded DNA templates in a sequence-independent manner, however the ability of the ZaP domain to interact with additional nucleic acid structures (e.g., RNA) has so far not yet been investigated \[[@B68-genes-06-00325],[@B69-genes-06-00325]\]. Interestingly, a recent high throughput screen identified PHF6 and other ZaP-containing proteins amongst a list of putative mRNA-interactors \[[@B70-genes-06-00325]\]. Moreover, the PHF6 ZaP1 domain was observed to have nucleolar localization in the absence of the NoLS and a single point mutation of a zinc ion stabilizing residue (C99F) within ZAP1 resulted in the ablation of PHF6 nucleolar localization \[[@B59-genes-06-00325]\]. In another study, the loss of both NLSs and the NoLS resulted in the nuclear, but not nucleolar, localization of PHF6 \[[@B15-genes-06-00325]\]. Taken together, these data suggest that additional interactions may be necessary to ensure the recruitment of PHF6 to the nucleoplasm and nucleolus.

4.2. PHF6 Interacting Partners
------------------------------

### 4.2.1 [Nu]{.ul}cleosome [R]{.ul}emodelling and [D]{.ul}eacetylation (NuRD) complex

We have previously demonstrated PHF6 to endogenously co-purify with multiple constituents of the NuRD chromatin remodelling complex (CHD3/4, HDAC1, and RBBP4/7) (see [Figure 2](#genes-06-00325-f002){ref-type="fig"}A), a transcriptional regulator with several gene targets that influence embryogenesis, oncogenesis, neurogenesis, and hematopoiesis \[[@B14-genes-06-00325],[@B71-genes-06-00325],[@B72-genes-06-00325],[@B73-genes-06-00325],[@B74-genes-06-00325],[@B75-genes-06-00325],[@B76-genes-06-00325],[@B77-genes-06-00325],[@B78-genes-06-00325]\]. The NuRD core complex has the ability to catalyze ATP-dependent nucleosome remodelling and histone deacetylation at its gene targets through its CHD and HDAC subunits, respectively \[[@B79-genes-06-00325],[@B80-genes-06-00325]\], but the transcriptional outcome of its targets is dependent upon its collective associations with other activators (e.g., P300) and repressors (e.g., LSD1) \[[@B81-genes-06-00325],[@B82-genes-06-00325]\]. Several NuRD interactors also possess zinc finger domains with the ability to target the complex to gene targets through DNA sequence-specific interactions (e.g., IKAROS, SALL1, BCL11B), thus the binding affinity of PHF6 to dsDNA may favour the association of NuRD to a distinct subset of its gene targets \[[@B83-genes-06-00325],[@B84-genes-06-00325],[@B85-genes-06-00325],[@B86-genes-06-00325]\].
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Functional comparison of human proteins expressing PZP motifs and/or ZaP domains.

  Protein          Uniprot Accession \#   Function                            PZP Motif or ZaP Domain   Amino Acid Residues    Reference
  ---------------- ---------------------- ----------------------------------- ------------------------- ---------------------- -------------------------------------------------
  PHF6             Q8IWS0                 Transcriptional regulation          ZaP (x2)                  14--134, 209--332      \[[@B14-genes-06-00325],[@B87-genes-06-00325]\]
  BRPF1            P55201                 MOZ/MORF-dependent H3 acetylation   PZPM                      273--450               \[[@B88-genes-06-00325]\]
  BRPF2            O95696                 MOZ/MORF-dependent H3 acetylation   PZPM                      214--391               \[[@B88-genes-06-00325]\]
  BRPF3            Q9ULD4                 MOZ/MORF-dependent H3 acetylation   PZPM                      188--389               \[[@B88-genes-06-00325]\]
  G2E3             Q7L622                 E3 ubiquitin-protein ligase         ZaP                       11--130                \[[@B89-genes-06-00325]\]
  JADE-1           Q6IE81                 HBO1-dependent H4 acetylation       PZPM                      203--371               \[[@B88-genes-06-00325]\]
  JADE-2           Q9NQC1                 HBO1-dependent H4 acetylation       PZPM                      199--367               \[[@B88-genes-06-00325]\]
  JADE-3           Q92613                 HBO1-dependent H4 acetylation       PZPM                      200--368               \[[@B88-genes-06-00325]\]
  JMJD2A (KDM4A)   O75164                 H3K9/H3K36 demethylase              PZPM                      665--887               \[[@B90-genes-06-00325]\]
  JMJD2B (KDM4B)   O94953                 H3K9 demethylase                    PZPM                      681--909               \[[@B90-genes-06-00325]\]
  JMJD2C (KDM4C)   Q9H3R0                 H3K9/H3K36 demethylase              PZPM                      642--867               \[[@B90-genes-06-00325]\]
  MLL1 (KMT2A)     Q03164                 H3K4 methyltransferase              PZPM                      1566--1980             \[[@B91-genes-06-00325]\]
  MLL2 (KMT2D)     O14686                 H3K4 methyltransferase              ZaP (x2)                  63--220, 5029--5139    \[[@B92-genes-06-00325]\]
  MLL3 (KMT2C)     Q8NEZ4                 H3K4 methyltransferase              ZaP (x2)                  131--333, 4399--4509   \[[@B93-genes-06-00325]\]
  MLL4 (KMT2B)     Q9UMN6                 H3K4 methyltransferase              PZPM                      1335--1688             \[[@B93-genes-06-00325]\]
  PHF7             Q9BWX1                 Binds chromatin                     ZaP                       30--147                \[[@B94-genes-06-00325]\]
  PHF11            Q9UIL8                 Transcriptional regulation          ZaP                       42--162                \[[@B95-genes-06-00325]\]
  PHF14            O94880                 Transcriptional regulation          PZPM                      319--501               \[[@B96-genes-06-00325]\]
  RAI1             Q7Z5J4                 Transcriptional regulation          ZaP                       1780--1905             \[[@B97-genes-06-00325]\]
  TCF20            Q9UGU0                 Transcriptional regulation          ZaP                       1789--1935             \[[@B98-genes-06-00325]\]

Many NuRD interactors (e.g.,SALL1, BCL11B, FOG-1) interface with the RBBP4 subunit through a conserved amino acid consensus sequence that is shared by PHF6 (aa 152--171) \[[@B69-genes-06-00325],[@B99-genes-06-00325],[@B100-genes-06-00325]\]. Indeed, Liu *et al.* confirmed a direct PHF6-RBBP4 interaction, and subsequently resolved the crystal structure to show that a PHF6 peptide (aa 162--170) peptide occupies a binding pocket located upon the surface of the RBBP4 β propeller \[[@B69-genes-06-00325],[@B101-genes-06-00325]\]. Interestingly, the PHF6 NoLS sequence overlaps with the RBBP4 binding domain, suggesting that these two activities may be mutually exclusive. Consistent with this assertion, the PHF6-NuRD/RBBP4 interaction was only found to occur in the nucleoplasm, and not within the nucleolus \[[@B14-genes-06-00325]\].

### 4.2.2 RNA [P]{.ul}olymerase II [A]{.ul}ssociated [F]{.ul}actor [1]{.ul} (PAF1)

Aside from NuRD, Phf6 interacts with multiple subunits of the Paf1 transcriptional elongation complex (Paf1, Leo1, Cdc73, Ctr9) (see [Figure 2](#genes-06-00325-f002){ref-type="fig"}B), which is necessary to mediate proper neurogenesis in mice \[[@B87-genes-06-00325]\]. In this study, *Phf6* and *Paf1* shRNA was electroporated into mouse cerebral cortices, resulting in impaired neuronal migration between E14 and E19. Using gene expression arrays, the authors identified *Neuroglycan C/Chrondroitin Sulfate Proteoglycan 5* (*NGC/CSPG5*) as a commonly regulated gene target, and when the *NGC/CSPG5* transcript was electroporated into cortical tissue alongside *Phf6* shRNA, the neuronal migration phenotype was rescued \[[@B87-genes-06-00325]\]. These findings are strikingly similar to those of Franzoni *et al.* who also ectopically expressed *Phf6* to rescue neuronal migration defects that accompanied premature expression of miR-128 in the developing neocortices of mice \[[@B20-genes-06-00325]\]. Interestingly, Paf1 also associates with the RNA Polymerase I machinery that is responsible for transcribing rRNA from rDNA genes, providing a potential means through which nucleolar Phf6 may be able to regulate rDNA gene expression \[[@B102-genes-06-00325]\].

### 4.2.3 Additional Interactions

In 2013, two independent studies identified an interaction between PHF6 and UBF (see [Figure 2](#genes-06-00325-f002){ref-type="fig"}C) \[[@B59-genes-06-00325],[@B87-genes-06-00325]\], an rDNA transcriptional activation factor that associates with the RNA Pol I pre-initiation complex \[[@B103-genes-06-00325],[@B104-genes-06-00325]\]. In contrast to *NGC/CSPG5*, where PHF6 activates transcription, Wang *et al.* report that PHF6 represses rRNA transcription \[[@B59-genes-06-00325]\]. Moreover, they also report that a loss of PHF6 results in increased genomic instability at rDNA genes and a cell cycle delay at G2/M. While this was the first indication of a nucleolar function for PHF6, it has also been reported to interact with PRPF8 and SNRNP200, both constituents of the U4/U6-U5 tri-snRNP pre-mRNA splicing ribonucleoprotein complex \[[@B14-genes-06-00325]\].

![PHF6 interacting proteins. PHF6 associates with (**A**) the NuRD complex via a direct interaction between amino acid residues 162--170 with the β propeller surface of RBBP4; (**B**) the PAF1 complex; and (**C**) UBF, via its ZaP1 domain.](genes-06-00325-g002){#genes-06-00325-f002}

4.3. PHF6 Is a Putative Phosphoprotein
--------------------------------------

Aside from these direct studies investigating PHF6 interactions, several phosphoproteomic screens have identified PHF6 peptides, suggesting that it is regulated by phosphorylation \[[@B105-genes-06-00325],[@B106-genes-06-00325],[@B107-genes-06-00325],[@B108-genes-06-00325]\]. In one study, the PHF6 T358 residue was identified as a target of the ATM DNA damage checkpoint kinase and the loss of PHF6 correlated with the accumulation of phosphorylated γH2AX \[[@B10-genes-06-00325],[@B59-genes-06-00325],[@B105-genes-06-00325]\]. Interestingly, the R342X mutation associated with severe BFLS, and also identified in T-ALL and AML patients would truncate this phosphorylation site. While the functional importance of T358 phosphorylation remains to be determined, one possibility is that it serves as a checkpoint response to negatively regulate rDNA transcription (e.g., via RNA Pol I inhibition) \[[@B109-genes-06-00325]\].

Two other studies have identified the phosphorylation of three serine residues (S145; S154; and S155) during mitosis and in response to T-cell receptor signalling \[[@B106-genes-06-00325],[@B107-genes-06-00325]\]. Interestingly, S145 phosphorylation is only ever observed in combination with phosphorylation at S155. Other high throughput screens indicate that S145 is a Polo-like kinase 1 (PLK1) target; consistent with its situation in a PLK1 consensus sequence; while phosphorylation at S155 provides a binding site for the polo binding domain of PLK1 (PBD); suggesting a mechanism whereby phosphorylation at S155 primes S145 for PLK1-mediated phosphorylation (see [Figure 3](#genes-06-00325-f003){ref-type="fig"}) \[[@B108-genes-06-00325],[@B110-genes-06-00325],[@B111-genes-06-00325]\]. Indeed PLK1 inhibition reduces S145 phosphorylation with concomitant accumulation of singularly phosphorylated S155 peptide \[[@B108-genes-06-00325],[@B112-genes-06-00325]\]. Interestingly, another screen identified S155 as a candidate substrate for CDK2 phosphorylation, and CDK2 inhibition interferes with the ability of PHF6 to localize to the nucleolus \[[@B113-genes-06-00325],[@B114-genes-06-00325]\]. While the exact mechanism of this serine phosphorylation network within PHF6 requires more direct validation; it should be noted that PLK1 and CDK2 are highly active during S and G~2~ phase when nucleolar size and the rate of ribosome biogenesis is higher relative to G~1~ \[[@B115-genes-06-00325],[@B116-genes-06-00325]\]. Moreover, these phosphorylation sites are directly adjacent to the NoLS. Thus, we speculate that these phosphorylation events may promote shuttling of PHF6 between the nucleoplasm and nucleolus in response to external needs, such as compensation for the increased rates of rRNA synthesis that precede cytokinesis or following T-cell receptor activation during lymphogenesis.

![Model for the putative CDK2- and PLK1-dependent phosphorylation of PHF6. Large-scale proteomic studies identified PHF6 Ser-145, -154, and -155 as phosphorylated residues. The phosphorylation of these sites during mitosis or in response to T-cell receptor signalling likely occurs through a mechanism whereby (**A**) CDK2 phosphorylates Ser-155, allowing recognition by the Polo-binding domain (PBD) of PLK1 (**B**), which subsequently phosphorylates Ser-145, which is situated in a PLK1 consensus sequence (143-EESFNE-148), resulting in PHF6 becoming dually phosphorylated at these two sites (**C**).](genes-06-00325-g003){#genes-06-00325-f003}

5. Perspectives and Future Directions
=====================================

5.1. Predicting Clinical Outcomes for Patients Expressing PHF6 Loss-of-Function
-------------------------------------------------------------------------------

The PHF6 protein is important for both faithful development and tumour suppression, yet only 6.5% of germline *PHF6* mutations (see [Table 1](#genes-06-00325-t001){ref-type="table"}) are associated with cancer \[[@B29-genes-06-00325],[@B31-genes-06-00325]\]. To explain why not all BFLS patients develop cancer, one consideration is that BFLS patients primarily have missense mutations that are likely functionally hypomorphic, whereas somatic *PHF6* mutations causing cancer are frameshift, nonsense, or deletions that are in all likelihood functionally null. In addition, BFLS patients would still require a second mutation (e.g., *TLX1*) within hematopoietic cells. Since female Coffin--Siris patients have a similar type of mutation to those individuals with T-ALL, they may be at greater risk for developing cancer. However, female patients with *de novo* germline deletions of *PHF6* all have skewed X-chromosome inactivation in the blood, which may explain why hematopoietic cancers have so far not been observed.

5.2. Developmental Role of PHF6
-------------------------------

The PHF6 interactors identified to date suggest that PHF6 is a multifaceted regulator of transcription working with the NuRD chromatin remodelling complex (or UBF) to repress or activate transcriptional initiation, and with the PAF1 complex in controlling transcriptional elongation ([Figure 4](#genes-06-00325-f004){ref-type="fig"}A). While these events may appear as disparate aspects of transcriptional control, they could be intimately linked. Indeed, many studies of IKAROS, a chromatin adaptor protein with DNA-binding zinc finger motifs, show that it can interact with both NuRD and the CDK9 catalytic subunit of positive-transcription elongation factor b (P-TEFb) \[[@B117-genes-06-00325],[@B118-genes-06-00325],[@B119-genes-06-00325]\]. Recent work has shown that IKAROS can recruit NuRD to specific target genes but it also interacts in a larger complex containing both NuRD and P-TEFb, in which IKAROS permits the transfer of protein phosphatase 1α (PP1α) to CDK9, which subsequently phosphorylates Ser-2 residues in the RNA pol II C-terminal domain (CTD), releasing RNA Pol II from promoter-proximal pausing to initiate elongation \[[@B119-genes-06-00325]\]. Thus, it is possible that PHF6 may interact within a NuRD-PAF1 supercomplex to promote productive elongation (see [Figure 4](#genes-06-00325-f004){ref-type="fig"}B), although the existence of such a complex has yet to be defined.

In conducting future investigations to elucidate the transcriptional roles of such PHF6-containing complexes, it will be important to identify all PHF6 target genes through tissue-specific ChIP-Seq as a starting point to assess which PHF6 targets are PAF1 regulated, which ones require the recruitment of NuRD, and which ones might utilize both complexes. Already, ChIP-Seq experiments for the NuRD constituents CHD4 and MBD3 indicate an enrichment of binding sites in gene bodies and well-defined peaks at transcriptional start site (TSS) regions \[[@B78-genes-06-00325],[@B120-genes-06-00325]\]. Similarly, a recent PHF6 ChIP-Seq dataset generated from Jurkat cells presents binding sites that are predominantly located throughout gene bodies and within the proximal promoter \[[@B58-genes-06-00325]\]. Nonetheless, dissecting the different mechanisms of transcriptional regulation through the identification of target genes will allow for the better definition of relevant developmental pathways (e.g., neurogenesis, hematopoiesis) that become compromised in patients with BFLS, T-ALL, and/or AML. In this regard, the recent findings of a network whereby neurogenesis depends upon the timely expression of *PHF6* to positively regulate *NGC/CSPG5* (via PAF1) to ensure proper cortical neuron migration, and miR-128 to negatively regulate *PHF6*, which allows for subsequent neuronal maturation, represent the first clear model of a developmental role for *PHF6* \[[@B20-genes-06-00325],[@B87-genes-06-00325]\]. Moreover, PHF6 binding sites from the Jurkat ChIP-Seq dataset are found within genes responsible for cell cycle regulation, cell morphology mechanisms, and cell signalling pathways mediating axonal guidance \[[@B58-genes-06-00325]\]. Interestingly, PHF6 binds the *NOTCH1* and *RUNX1* promoters, genes that have mutations that are co-expressed with *PHF6* mutations in T-ALL and AML, respectively \[[@B8-genes-06-00325],[@B48-genes-06-00325]\]. Furthermore, the fact that NOTCH1 was itself found to bind the *PHF6* promoter in a T-ALL cell line suggests that hematopoietically expressed PHF6 may participate within a feedback regulation network \[[@B22-genes-06-00325]\]. Therefore, carrying out these types of multidisciplinary approaches in primary tissues will be crucial to more fully understanding the functional roles of PHF6.

![Model for PHF6-dependent transcriptional regulation at developmental or rDNA gene targets. (**A**) At developmental genes, PHF6 recruits NuRD to promoters to either activate or repress transcription. Similarly, PHF6 can regulate transcriptional elongation at developmental genes through its interaction with the PAF1 complex. (**B**) Another possible mechanism is that PHF6 interactions with NuRD and PAF1 occur at the same gene whereby PHF6 promotes the formation of a NuRD-PAF1 supercomplex to allow for productive elongation. The existence of a PHF6-mediated supercomplex would be analogous to an IKAROS-driven complex previously described \[[@B119-genes-06-00325]\]. (**C**) At rRNA genes, PHF6 interacts with UBF to mediate the initiation of rRNA transcription (left). Promoter regulation may also involve NuRD, although this remains to be shown. Similarly, PHF6-PAF1 may mediate rRNA transcriptional elongation, although experimental validation is still required.](genes-06-00325-g004){#genes-06-00325-f004}

5.3 Nucleolar Role of PHF6
--------------------------

In addition to developmental gene targets, PHF6 may utilize similar complexes to control rDNA transcription, as outlined in [Figure 4](#genes-06-00325-f004){ref-type="fig"}. In this regard, both NuRD and PAF1 have been demonstrated to contribute to the transcriptional competency of rDNA genes \[[@B102-genes-06-00325],[@B121-genes-06-00325],[@B122-genes-06-00325]\]. Moreover, control of rRNA levels may also involve nucleolar localization of PHF6 since the NuRD interaction motif overlaps with the NoLS and is directly adjacent to the Ser 154/155, which were proposed to be phosphorylated by CDK2 and whose inhibition prevents PHF6 from localizing to the nucleolus \[[@B101-genes-06-00325],[@B113-genes-06-00325],[@B114-genes-06-00325]\]. While it is an attractive hypothesis, further experiments are still required to delineate the importance of PHF6 to the regulation of ribosome biogenesis. Still, the transcription of rRNA accounts for as much as half of all cellular transcription, with ribosome biogenesis rates correlating positively to nucleolar size \[[@B59-genes-06-00325],[@B123-genes-06-00325]\].

In many cancers, it is the hyperactivation of ribosome biogenesis that contributes to the pathology, with large nucleoli correlating to poorer clinical outcomes \[[@B124-genes-06-00325]\]. Given that PHF6 is reported as a negative regulator of rDNA transcription, PHF6 loss-of-function is consistent with increased ribosome biogenesis and contributing to clonal growth in T-ALL. Indeed several T-ALL mutations have been identified in genes encoding ribosomal proteins (e.g.; *RPL5, RPL10, RPL11, RPL22*), whereas others (e.g., *NOTCH1*, *PTEN, FBXW7*) target aspects of the cap-dependent mRNA translation machinery, as has been the subject of recent reviews \[[@B125-genes-06-00325],[@B126-genes-06-00325]\]. For some of these genes, a mechanism supporting translational hyperactivation remains unclear, with De Keersmaecker and colleagues arguing for a model where it is the reduction of translational fidelity that contributes to tumorigenesis \[[@B125-genes-06-00325],[@B126-genes-06-00325]\]. It may also be the case that defective ribosomes, or their individual subunits, have altered extraribosomal functions, allowing tumour cells to overcome cell cycle checkpoints or interfere with tissue-specific developmental pathways \[[@B126-genes-06-00325],[@B127-genes-06-00325]\]. In this regard, interactions between PHF6 and ribosomal proteins have been identified and as such, may also impinge upon ribosomal and extraribosomal functions \[[@B14-genes-06-00325]\].

In neurons, large nucleoli facilitate the sufficient supply of ribosomes to growing neurites to accommodate local demands for translation \[[@B128-genes-06-00325]\]. Indeed many developmental intellectual disability diseases (e.g., Cockayne syndrome, Rett syndrome) and acquired neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease) are associated with reduced levels of ribosome biogenesis \[[@B129-genes-06-00325],[@B130-genes-06-00325]\]. Although hyperactive ribosome biogenesis would appear paradoxical with BFLS, a potential explanation may exist by considering the loss of MeCP2, which is responsible for Rett syndrome \[[@B131-genes-06-00325]\]. In this example, MeCP2 binds methylated CpG DNA, a mark for rDNA silencing \[[@B132-genes-06-00325]\], and contributes to heterochromatin formation \[[@B133-genes-06-00325]\]; yet, rather than hyperactivating rRNA synthesis, the loss of MeCP2 correlates with reduced nucleolar size \[[@B134-genes-06-00325]\].

6. Conclusion
=============

Since the discovery of PHF6 as the cause of BFLS in 2002, the precise function of the protein has remained elusive. Nonetheless, it is becoming clear that PHF6 is a highly dynamic chromatin adaptor protein, containing two ZaP domains that facilitate its interactions with nucleic acids and a growing number of interaction partners (NuRD, PAF1, UBF) to regulate transcription. Moreover, several potential phosphorylation sites, its interaction with rDNA, and its ability to shuttle between the nucleolus and nucleoplasm suggest that it may be a key regulator of ribosome biogenesis. The generation of transgenic mouse models with BFLS-like, T-ALL-like, or AML-like *PHF6* mutations, will certainly augment the dissection of the molecular mechanisms driving BFLS and leukemia. In making use of such models, further characterization of the functional roles of PHF6 may thus facilitate the development of novel therapeutics for these distinct disorders.
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